In re Nexium (Esomeprazole) Antitrust Litigation, No. 1:12-md-02409-WGY (D. Mass.) (representing pharmaceutical wholesaler and proposed class of direct purchasers of the prescription drug Nexium, alleging that the brand manufacturer entered into illegal reverse-payment agreements with certain generic manufacturers to delay the entry of more affordable generic Nexium).

In this case, nicknamed the Doryx case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a class of direct purchasers of Warner-Chilcott’s branded drug, Doryx (delayed-release doxycycline hyclate).  The case alleges that Warner-Chilcott and its licensor, Mayne Pharmaceuticals, to forestall competition from less-expensive generic versions of Doryx, hatched an... READ MORE

In this case, nicknamed Skelaxin, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a proposed class of direct purchasers of the muscle relaxant drug Skelaxin (metaxalone), which has been on the market, without generic competition, since the 1960s.  The suit alleges that the brand manufacturer (King) and a generic... READ MORE

In this case, nicknamed Lipitor, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Pfizer’s branded blockbuster cholesterol drug Lipitor (atorvastatin calcium), and direct purchasers of generic Lipitor manufactured by Ranbaxy.  The case alleges that Pfizer and its predecessors and affiliates engaged in... READ MORE

In the Effexor XR case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Wyeth’s (now Pfizer’s) branded antidepressant drug Effexor XR (extended-release venlafaxine hydrochloride capsules).  The class also includes direct purchasers of generic versions of Effexor XR from Teva, Wyeth’s co-defendant and... READ MORE

Faruqi & Faruqi represents a proposed class of pediatricians and pediatric practice groups challenging Sanofi-Pasteur, Inc.’s illegal maintenance of a monopoly on the children’s vaccine Menactra in violation of  § 2 of the Sherman Act.  Plaintiffs allege a scheme where Sanofi-Pasteur employs a series of anticompetitive and exclusionary bundling and... READ MORE

Faruqi & Faruqi represents a proposed class of users of wire harnesses in automobiles against parts manufacturers who pleaded guilty to Department of Justice charges of an conspiracy to fix prices, violating § 1 of the Sherman Act.  Defendants are manufacturers of automotive wiring harnesses.  Defendants drew the attention of... READ MORE

Faruqi & Faruqi represents a proposed class of homeowners challenging GMAC’s pattern and practice of forcing owners of properties to purchase excessive high-premium flood insurance.  Plaintiffs allege that GMAC’s conduct violates the federal Truth in Lending Act and breaches the mortgage contract between homeowners and GMAC.  Plaintiffs also allege that... READ MORE

Faruqi & Faruqi represents a proposed class of e-book purchasers alleging a horizontal conspiracy among book publishers and e-book sellers in the United States to raise, fix, stabilize and maintain retail prices of e-books.

Faruqi & Faruqi represents a proposed class of condominium owners challenging GMAC’s pattern and practice of forcing owners of condominium units to purchase excessive high-premium flood insurance.  Plaintiffs allege that GMAC’s conduct violated the federal Truth in Lending Act and breaches the mortgage contract between condominium unit owners and GMAC. ... READ MORE

Faruqi & Faruqi represents a proposed class of silver traders that transacted in COMEX silver futures and option contracts.  This lawsuit, against affiliates of JP Morgan and others, challenges defendants’ alleged conspiracy to manipulate prices of COMEX silver futures and options in violation of § 1 of the Sherman Act... READ MORE

Faruqi & Faruqi represented a class of direct purchasers alleging producers and sellers of ready-mixed concrete conspired to fix prices in violation of § 1 of the Sherman Act.  This case settled for $18.5 million in 2011.

In the Prandin case, Faruqi & Faruqi represent a pharmaceutical wholesaler and a proposed class of direct purchasers of Novo Nordisk’s branded diabetes drug Prandin (repaglinide).   The case alleges that Novo Nordisk engaged in an overarching anticompetitive scheme to block less-expensive generic Prandin competition and thereby force direct purchasers to... READ MORE

Marchese v. Cablevision Systems Corporation, No. 2:10-cv-02190 (D.N.J.) (representing a proposed class of direct purchasers of two-way cable services from Cablevision, accusing Cablevision of illegally tying those services to rentals of a Cablevision-supplied set-top box)

In the Wallach case, Faruqi & Faruqi, LLP represents a proposed class of purchasers of Class 8 truck transmissions — the types of transmissions used in 18-wheelers.  The case alleges that the dominant manufacturer of the transmissions, Eaton Corporation, and several truck manufacturers, engaged in an exclusive dealing conspiracy that... READ MORE

Faruqi & Faruqi represents a proposed class of direct purchasers challenging a conspiracy, by the leading suppliers of Titanium Dioxide in the U.S. and the world,  to fix prices and allocate markets for Titanium Dioxide, in violation of § 1 of the Sherman Act.  Plaintiffs have alleged that defendants E.I.... READ MORE

Faruqi & Faruqi represents a proposed class of Division 1 college athletes and former athletes against the NCAA and its licensing agent alleging conspiracy to preclude athletes from profiting from use of their images in violation of  § 1 of the Sherman Act.

Plaintiffs allege Defendants (Reddy Ice, Arctic Glacier, and Home City Ice), the three largest companies in the United States that manufacture and distribute packaged ice, conspired not to compete with each other in violation of the federal antitrust laws.

Faruqi & Faruqi represented a class of direct purchasers of drugs Indocin and NeoProfen alleging monopolization under §§ 1 and 2 of the Sherman Act and § 7 of the Clayton Act. This case settled in 2011.

In the Blood Reagents price fixing case, Faruqi & Faruqi represents a proposed class of direct purchasers of blood reagent products, challenging conspiracy to fix prices, in violation of § 1 of the Sherman Act.  Plaintiffs have alleged that defendants Immucor and Ortho-Clinics Diagnostics, a subsidiary of Johnson & Johnson,... READ MORE